Jarno Drost obtained a M.Sc. degree in Biomolecular Sciences from the Free University of Amsterdam (with honors). In 2012, he obtained his Ph.D. at the Netherlands Cancer Institute in the lab of prof. dr. Reuven Agami. His research led to the identification of BRD7 – a novel tumor suppressor gene acting in the P53 pathway – and the discovery that P53 binds and regulates enhancer elements through the production of enhancer RNAs. Next, he joined the lab of prof. dr. Hans Clevers as a post-doctoral fellow. Here, he developed colorectal cancer (CRC) progression models by introducing combinations of the most commonly mutated CRC genes in human intestinal organoids using CRISPR/Cas9 genome editing. Using these models, his research revealed that mutation of four genes transforms healthy stem cells into metastasizing adenocarcinoma cells. Moreover, he established organoid cultures from healthy and cancerous prostate tissue and used this model for the identification of multipotent luminal progenitor cells in human prostate. His postdoctoral work was awarded a Dutch NWO Veni career grant for talented postdoctoral researchers and the Hubrecht postdoc of the year award 2017.
In 2016, Jarno was appointed as a group leader in the Princess Máxima Center for pediatric oncology. His group studies the molecular alterations underlying pediatric renal and rhabdoid tumors and aims to develop novel therapies. He received a prestigious Young Investigator/Bas Mulder Award from the Dutch Cancer Society to support the development of renal tumor organoids.
2018 Dr. Patrick Hanlo Award for best post-doctoral researcher 2017, Hubrecht Institute, Utrecht, the Netherlands
2017 Young Investigator Grant/Bas Mulder Award, Dutch Cancer Society (KWF)/Alpe d’HuZes. Prestigious national grant for talented young researchers (project # 10218)
2013 Veni career grant for talented post-doctoral researchers (NWO # 91614138)